Arno Therapeutics, Inc.

ARNI

US0425642032

Pharmaceuticals

Delayed OTC Markets Other stock markets 15:25:51 23/04/2024 BST			5-day change	1st Jan Change
0.0003 ^USD	+417.24%		-.--%	+200.00%

2017	Arno Therapeutics, Inc. Terminates Licensing Agreement with Ohio State University	CI
2017	Arno Therapeutics Seeks Acquisitions	CI

Arno Therapeutics Seeks Acquisitions

January 04, 2017 at 05:00 am

Arno Therapeutics, Inc. (OTCPK:ARNI) is seeking acquisitions and potential development opportunities to grow further.

Latest news about Arno Therapeutics, Inc.

Arno Therapeutics, Inc. Terminates Licensing Agreement with Ohio State University	25/12/17	CI
Arno Therapeutics Seeks Acquisitions	04/01/17	CI
Arno Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016	14/11/16	CI
Arno Therapeutics, Inc. announced that it has received $2.725498 million in funding from Pontifax Ltd., OPKO Health, Inc., Perceptive Advisors LLC, Commercial Street Capital, LLC, Bonderman Family Limited Partnership, Auriga Capital Management, LLC	03/11/16	CI
Arno Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016	22/08/16	CI
Arno Therapeutics, Inc. Updates Clinical Development of Onapristone Plus Zytiga	16/08/16	CI
Arno Therapeutics, Inc. announced that it expects to receive $2.98 million in funding from a group of investors	14/08/16	CI
Arno Therapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016	17/05/16	CI
Arno Therapeutics, Inc. Announces Consolidated Unaudited Financial Results for the Fourth Quarter and Full Year Ended December 31, 2015	30/03/16	CI
Arno Therapeutics, Inc. Appoints Jay Moorin to its Board of Directors	13/01/16	CI
Arno Therapeutics, Inc. announced that it has received $5.28 million in funding from Commercial Street Capital, LLC, and other investors.	11/01/16	CI
Arno Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015	16/11/15	CI
Arno Therapeutics, Inc. Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains	21/10/15	CI
Arno Therapeutics, Inc. announced that it expects to receive $2.1 million in funding from Commercial Street Capital, LLC and other investors.	20/10/15	CI
Arno Therapeutics, Inc. Announces Data Demonstrates Novel Antimicrobial Activity of AR-12	19/09/15	CI
Arno Therapeutics, Inc. Announces Resignation of Lawrence A. Kenyon as Chief Operating Officer and Chief Financial Officer, Effective September 15, 2015	11/09/15	CI
Arno Therapeutics, Inc. Receives Authorization to Proceed with Modified Phase I/II Trial Evaluating Onapristone in Prostate Cancer	18/08/15	CI
Arno Therapeutics, Inc. Announces Unaudited Financial Results for the Second Quarter and Six Months Ended June 30, 2015	14/08/15	CI
Arno Therapeutics, Inc. Announces Cooperative Research and Development Agreement with US Army Medical Research Institute of Infectious Diseases to Test Antiviral Activity of AR-12	03/06/15	CI
Arno Therapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015	15/05/15	CI
Arno Therapeutics, Inc. Announces Promising Data Supporting the Ongoing Clinical Development Program for Lead Compound Onapristone	13/05/15	CI
Arno Therapeutics Receives USPTO Notice of Allowance for Two Important Patents Covering Lead Compound Onapristone	07/05/15	CI
Arno Therapeutics, Inc. Announces Consolidated Unaudited Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014	01/04/15	CI
Arno Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	30/03/15	CI
Arno Therapeutics to Present Data Further Validating Diagnostic Development of CDx for Onapristone at San Antonio Breast Cancer Symposium 2014	09/12/14	CI

Arno Therapeutics, Inc. is an early-stage company focused on developing products for the treatment of cancer and other life threatening diseases. The Company's product development pipeline includes Onapristone, AR-42, and AR-12 and analogs. Onapristone is indicated for endometrial, prostate and breast cancer indications. AR-42 is provided for hematological malignancies and solid tumors indications. AR-12 is offered for solid tumors and hematological malignancies, and various anti-microbial targets. Onapristone is a type 1 anti-progestin hormone blocker that has considerable anti-tumor activity in patients with breast cancer. The Company is engaged in developing and commercializing AR-42, which is an oral cancer therapy in early clinical development. AR-42 is a spectrum deacetylase inhibitor of both histone and non-histone proteins, which has potency and activity in solid tumors and hematological malignancies. AR-12 is an orally available cancer treatment.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
ARNO THERAPEUTICS, INC.	+200.00%	14.8K
CSL LIMITED	-1.26%	89.46B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.74B
BIOGEN INC.	-8.51%	33.03B
UCB	+55.32%	24.68B
BIOMARIN PHARMACEUTICAL INC.	-16.57%	15.12B
INCYTE CORPORATION	-9.08%	12.81B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.11%	11.79B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.61%	11.64B
SWEDISH ORPHAN BIOVITRUM AB	+7.79%	8.9B

Biopharmaceuticals

Arno Therapeutics, Inc.

Equities

ARNI

US0425642032

Pharmaceuticals

Arno Therapeutics Seeks Acquisitions

Latest news about Arno Therapeutics, Inc.

Chart Arno Therapeutics, Inc.

Company Profile

Sector Biopharmaceuticals